Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial.

IF 12 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Judith Wellens, Julie Vanderstappen, Sien Hoekx, Eva Vissers, Martijn Luppens, Lies Van Elst, Matthias Lenfant, Jeroen Raes, Muriel Derrien, Bram Verstockt, Marc Ferrante, Kristin Verbeke, Christophe Matthys, Séverine Vermeire, João Sabino
{"title":"Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial.","authors":"Judith Wellens, Julie Vanderstappen, Sien Hoekx, Eva Vissers, Martijn Luppens, Lies Van Elst, Matthias Lenfant, Jeroen Raes, Muriel Derrien, Bram Verstockt, Marc Ferrante, Kristin Verbeke, Christophe Matthys, Séverine Vermeire, João Sabino","doi":"10.1016/j.cgh.2025.08.005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background & aims: </strong>Dietary emulsifier consumption might promote intestinal inflammation, eventually leading to inflammatory bowel diseases. However, human data are scarce and involve a limited number of emulsifiers. We studied the effects of an emulsifier-free diet (EFD) and specific emulsifier supplementation.</p><p><strong>Methods: </strong>Sixty healthy participants followed an EFD for 2 weeks. Then, using a randomized placebo-controlled trial design, participants continued an EFD for 4 weeks with the addition of either carboxymethyl cellulose, polysorbate-80, carrageenan, soy lecithin, native rice starch, or no additives administered through brownies. Effects on cardiometabolic markers, gut microbiota, intestinal inflammation, and permeability were explored.</p><p><strong>Results: </strong>After 2 weeks of an EFD, cholesterol levels decreased (P = .00006). Under emulsifier supplementation, alpha diversity remained stable, yet microbial composition was affected by treatment and visit. Compared with placebo, concentrations of all short chain fatty acids were lower in those consuming carboxymethyl cellulose, which was mirrored by other emulsifiers, although not all reached significance. No differences in fecal calprotectin, C-reactive protein, serum lipopolysaccharide-binding protein, cholesterol levels, or other metabolic markers were observed between placebo and emulsifiers at the end of the intervention. Serum inflammatory and cardiometabolic proteins remained unchanged. In individuals consuming carrageenan, transcellular intestinal permeability increased (P = .04) compared with baseline.</p><p><strong>Conclusion: </strong>In this double-blind placebo-controlled exploratory trial, emulsifier supplementation lowered short chain fatty acid concentration compared with placebo. Emulsifier supplementation did not impact intestinal or systemic inflammation or metabolic endpoints. Cholesterol levels decreased after 2 weeks of an EFD. These results point towards potential intestinal benefits of limiting dietary emulsifiers in the diet, requiring further investigation.</p><p><strong>Clinicaltrials: </strong>gov, Number: NCT06552156.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Gastroenterology and Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cgh.2025.08.005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background & aims: Dietary emulsifier consumption might promote intestinal inflammation, eventually leading to inflammatory bowel diseases. However, human data are scarce and involve a limited number of emulsifiers. We studied the effects of an emulsifier-free diet (EFD) and specific emulsifier supplementation.

Methods: Sixty healthy participants followed an EFD for 2 weeks. Then, using a randomized placebo-controlled trial design, participants continued an EFD for 4 weeks with the addition of either carboxymethyl cellulose, polysorbate-80, carrageenan, soy lecithin, native rice starch, or no additives administered through brownies. Effects on cardiometabolic markers, gut microbiota, intestinal inflammation, and permeability were explored.

Results: After 2 weeks of an EFD, cholesterol levels decreased (P = .00006). Under emulsifier supplementation, alpha diversity remained stable, yet microbial composition was affected by treatment and visit. Compared with placebo, concentrations of all short chain fatty acids were lower in those consuming carboxymethyl cellulose, which was mirrored by other emulsifiers, although not all reached significance. No differences in fecal calprotectin, C-reactive protein, serum lipopolysaccharide-binding protein, cholesterol levels, or other metabolic markers were observed between placebo and emulsifiers at the end of the intervention. Serum inflammatory and cardiometabolic proteins remained unchanged. In individuals consuming carrageenan, transcellular intestinal permeability increased (P = .04) compared with baseline.

Conclusion: In this double-blind placebo-controlled exploratory trial, emulsifier supplementation lowered short chain fatty acid concentration compared with placebo. Emulsifier supplementation did not impact intestinal or systemic inflammation or metabolic endpoints. Cholesterol levels decreased after 2 weeks of an EFD. These results point towards potential intestinal benefits of limiting dietary emulsifiers in the diet, requiring further investigation.

Clinicaltrials: gov, Number: NCT06552156.

五种膳食乳化剂对炎症、渗透性和肠道微生物组的影响:一项安慰剂对照随机试验。
背景和目的:饮食中乳化剂的摄入可能会促进肠道炎症,最终导致炎症性肠病。然而,人类数据很少,而且涉及的乳化剂数量有限。本试验研究了无乳化剂日粮(EFD)和添加特定乳化剂的效果。方法:60名健康参与者进行了为期两周的EFD。然后,使用随机安慰剂对照试验设计,参与者继续EFD四周,添加羧甲基纤维素(CMC),聚山梨酸酯-80,卡拉胶,大豆卵磷脂,天然大米淀粉(NRS),或不通过布朗尼添加添加剂。研究了对心脏代谢指标、肠道微生物群、肠道炎症和通透性的影响。结果:EFD治疗2周后,胆固醇水平下降(p=0.00006)。在添加乳化剂的情况下,α多样性保持稳定,但微生物组成受处理和访问的影响。与安慰剂相比,服用CMC的人体内所有短链脂肪酸(SCFAs)的浓度都较低,其他乳化剂也反映了这一点,尽管并非所有乳化剂都达到显著水平。在干预结束时,安慰剂组和乳化剂组在粪便钙保护蛋白、CRP、LBP、胆固醇水平或其他代谢标志物方面没有观察到差异。血清炎症蛋白和心脏代谢蛋白保持不变。在食用卡拉胶的个体中,与基线相比,跨细胞肠通透性增加(p=0.04)。结论:在这项双盲安慰剂对照探索性试验中,与安慰剂相比,乳化剂的补充降低了SCFA浓度。乳化剂的补充不会影响肠道或全身炎症,也不会影响代谢终点。服用EFD两周后,胆固醇水平下降。这些结果表明,在饮食中限制乳化剂对肠道的潜在益处,需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
16.90
自引率
4.80%
发文量
903
审稿时长
22 days
期刊介绍: Clinical Gastroenterology and Hepatology (CGH) is dedicated to offering readers a comprehensive exploration of themes in clinical gastroenterology and hepatology. Encompassing diagnostic, endoscopic, interventional, and therapeutic advances, the journal covers areas such as cancer, inflammatory diseases, functional gastrointestinal disorders, nutrition, absorption, and secretion. As a peer-reviewed publication, CGH features original articles and scholarly reviews, ensuring immediate relevance to the practice of gastroenterology and hepatology. Beyond peer-reviewed content, the journal includes invited key reviews and articles on endoscopy/practice-based technology, health-care policy, and practice management. Multimedia elements, including images, video abstracts, and podcasts, enhance the reader's experience. CGH remains actively engaged with its audience through updates and commentary shared via platforms such as Facebook and Twitter.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信